Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: Results of a multicenter phase II study
D.S. McMeekin, A. Lisyanskaya, M. Crispens, A.M. Oza, P. Braly, D. Doering, E. Bayever, B. Michiels, M. MarkmanVolume:
114
Year:
2009
Language:
english
Pages:
5
DOI:
10.1016/j.ygyno.2009.04.034
File:
PDF, 230 KB
english, 2009